22,550
-5.05%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About L&C Bio Co
Its shares trade on KOSDAQ under the ticker 290650.KQ. It has been listed since 1 November 2018. In the fiscal year to 31 December 2025, it reported revenue of ₩85.48bn and a net loss of ₩138.17bn. At that date it held total assets of ₩456.64bn and shareholders' equity of ₩198.22bn.
L&C BIO Co., Ltd. develops soft tissue, allografts, and medical devices. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-11-01. The firm mainly manufactures and sells human tissue transplant materials used for tissue repair and filler. The firm also produces and sells human tissue-based medical devices and Cosmeceuticals. Its products are used in vascular surgeries, plastic surgeries, general surgeries and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 1 Nov 2018
- Website
- lncbio.co.kr ↗
Leadership
Pay as last reported
- Mr. Jae Ho LeeCo-Chief Executive Officer, Chief Financial Officer, Director
- Mr. Hwan Cheol LeeCo-Chief Executive Officer, Director, since 2025
- Mr. Hyeong Gu KimVice President, Director
- Mr. Hak Gyu BaeVice President
- Ms, Bang Hui HanVice President
- Mr. Gi Min KimAssistant Managing Director
- Mr. Gwang Yin LeeAssistant Managing Director
- Mr. Su Seong YimAssistant Managing Director
- Mr. Ruiheng ZhangOther Non-Executive Director
- Mr. Tae Seon JeonNon-Executive Independent Director, Internal Auditor
- Mr. Seong Jong ParkNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- L&C Bio Co Ltd develops soft tissue allografts for vascular and plastic surgeries in South Korea.
- The company manufactures human tissue transplant materials for tissue repair and filler applications.
- L&C Bio Co Ltd produces human tissue-based medical devices and Cosmeceuticals for medical use.
Weaknesses
- L&C Bio Co Ltd focuses on tissue transplant materials with limited diversification in product lines.
- The company's business is concentrated in South Korea with no international market expansion mentioned.
- L&C Bio Co Ltd has no mention of R&D investment in the provided facts.
Opportunities
- Expanding into international markets for soft tissue allografts and medical devices.
- Increasing demand for human tissue-based medical devices in the Health Care sector.
- Growing market for Cosmeceuticals in the South Korean consumer health industry.
Threats
- Competition from other biotechnology firms in the South Korean Health Care sector.
- Regulatory challenges for tissue transplant materials in the Health Care industry.
- Dependence on South Korea's market for medical device sales and tissue repair applications.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.